The Next-Generation Treatment for Aggressive form of Leukemia

47

Every year, around 19,520 new cases of patients with AML are diagnosed. Out of these, around 10,670 patients die of the same every year. These statistics have been provided by the American Cancer Society.

In the latest study, researchers from Purdue University are on the project of developing a series of specialized drug compounds that are capable of treating the most aggressive forms of leukemia. Around 30 percent of the patients with AML tend to have a mutation that is caused by the presence of a kinase –referred to as FLT3. This kinase is something that is responsible for making leukemia highly aggressive.

intim confirms that the given drug compounds tend to have immense potential to serve as the next-generation therapeutics for the treatment of AML –especially in the patients reporting cases of the cancer relapsing. The results of the study appear to be encouraging. This is because, with rapid advancements that take place in other forms of cancers in the recent era, the advancement with respect to the treatment of AML has been quite slow.

Drug Inhibitors to FLT3

Some of the existing inhibitors to FLT3 including Radapt have been given approval by the US FDA (United States Food & Drug Administration). Radapt has been successful in revealing positive outcomes in treating leukemia during the initial stages. Another inhibitor to FLT3 –Gilteritinib, has also received approval recently in 2018. However, there have been cases that patients who were receiving drug inhibitors often found the cancer relapse. This often happened due to the secondary mutations in the FLT3. Moreover, existing treatments are also not successful in treating relapsing cases.

Also Read: Bioengineered Solution to Boost Immunity in Leukemia Patients

A team of researchers led over by Herman O. Sintim –Professor of Chemistry in the Drug Discovery department at Purdue University, state that it has been successful in developing a series of compounds. The compounds are known to work not only on Acute Myeloid Leukemia that is common with mutations due to FLT3, but also on drug-resistant leukemia due to problematic mutations –like the gatekeeper F691L mutation. This causes the relapsing of cancer in some patients.
Effects of Drug Compounds on AML

Sintim confirms that the given drug compounds tend to have immense potential to serve as the next-generation therapeutics for the treatment of AML –especially in the patients reporting cases of the cancer relapsing. The results of the study appear to be encouraging. This is because, with rapid advancements that take place in other forms of cancers in the recent era, the advancement with respect to the treatment of AML has been quite slow.

Source: Cancer.gov | nih.gov